Monocytes and pyrophosphate promote mesenchymal stem cell viability and early osteogenic differentiation.
Bone Regeneration
/ drug effects
Cell Communication
/ drug effects
Cell Differentiation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Culture Media, Conditioned
Diphosphates
/ pharmacology
Down-Regulation
/ drug effects
Humans
Lipopolysaccharides
/ pharmacology
Materials Testing
Mesenchymal Stem Cells
/ drug effects
Monocytes
/ physiology
Osteogenesis
/ drug effects
Up-Regulation
/ drug effects
Cell-cell communication
Gene expression
MSC
Monocytes
Osteoinduction
Journal
Journal of materials science. Materials in medicine
ISSN: 1573-4838
Titre abrégé: J Mater Sci Mater Med
Pays: United States
ID NLM: 9013087
Informations de publication
Date de publication:
15 Jan 2022
15 Jan 2022
Historique:
received:
26
06
2021
accepted:
18
12
2021
entrez:
15
1
2022
pubmed:
16
1
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Pyrophosphate-containing calcium phosphate implants promote osteoinduction and bone regeneration. The role of pyrophosphate for inflammatory cell-mesenchymal stem cell (MSC) cross-talk during osteogenesis is not known. In the present work, the effects of lipopolysaccharide (LPS) and pyrophosphate (PPi) on primary human monocytes and on osteogenic gene expression in human adipose-derived MSCs were evaluated in vitro, using conditioned media transfer as well as direct effect systems. Direct exposure to pyrophosphate increased nonadherent monocyte survival (by 120% without LPS and 235% with LPS) and MSC viability (LDH) (by 16-19% with and without LPS). Conditioned media from LPS-primed monocytes significantly upregulated osteogenic genes (ALP and RUNX2) and downregulated adipogenic (PPAR-γ) and chondrogenic (SOX9) genes in recipient MSCs. Moreover, the inclusion of PPi (250 μM) resulted in a 1.2- to 2-fold significant downregulation of SOX9 in the recipient MSCs, irrespective of LPS stimulation or culture media type. These results indicate that conditioned media from LPS-stimulated inflammatory monocytes potentiates the early MSCs commitment towards the osteogenic lineage and that direct pyrophosphate exposure to MSCs can promote their viability and reduce their chondrogenic gene expression. These results are the first to show that pyrophosphate can act as a survival factor for both human MSCs and primary monocytes and can influence the early MSC gene expression. Graphical abstract.
Identifiants
pubmed: 35032239
doi: 10.1007/s10856-021-06639-y
pii: 10.1007/s10856-021-06639-y
pmc: PMC8761140
doi:
Substances chimiques
Culture Media, Conditioned
0
Diphosphates
0
Lipopolysaccharides
0
diphosphoric acid
4E862E7GRQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11Subventions
Organisme : the swedish research council
ID : 2018-02891
Informations de copyright
© 2022. The Author(s).
Références
J Mater Chem B. 2018 Aug 7;6(29):4765-4774
pubmed: 32254303
PLoS One. 2014 Feb 13;9(2):e89025
pubmed: 24551211
Calcif Tissue Int. 2016 Aug;99(2):199-208
pubmed: 27086348
Biomaterials. 2019 Mar;196:100-108
pubmed: 29598897
PLoS One. 2016 Oct 4;11(10):e0163530
pubmed: 27701417
Stem Cells. 2006 Dec;24(12):2744-52
pubmed: 16902195
Arthritis Res. 2001;3(4):242-6
pubmed: 11438042
Plast Reconstr Surg Glob Open. 2015 Aug 25;3(8):e491
pubmed: 26495204
Biomaterials. 2005 Jun;26(16):3249-57
pubmed: 15603820
Int J Mol Sci. 2021 Jan 23;22(3):
pubmed: 33498630
Sci Rep. 2020 Dec 17;10(1):22154
pubmed: 33335113
Front Immunol. 2018 Oct 09;9:2248
pubmed: 30356764
J Cell Mol Med. 2010 Apr;14(4):922-32
pubmed: 19243475
Nat Rev Immunol. 2011 Oct 10;11(11):762-74
pubmed: 21984070
Front Immunol. 2019 Apr 02;10:663
pubmed: 31001270
J Cell Physiol. 1979 Jan;98(1):81-94
pubmed: 216705
Biomaterials. 2013 Sep;34(28):6631-7
pubmed: 23747007
Biomaterials. 2011 Nov;32(32):8190-204
pubmed: 21835463
J Interferon Cytokine Res. 2019 Jun;39(6):375-382
pubmed: 30990360
Circulation. 2013 Jun 18;127(24):2442-51
pubmed: 23690466
Tissue Eng Part B Rev. 2011 Dec;17(6):393-402
pubmed: 21615330
Circ Res. 2010 Mar 5;106(4):712-9
pubmed: 20056916
NPJ Regen Med. 2018 Nov 29;3:22
pubmed: 30510772
Curr Osteoporos Rep. 2018 Apr;16(2):138-145
pubmed: 29508143
J Immunol. 2002 May 15;168(10):5310-7
pubmed: 11994489
Cytokine. 2008 May;42(2):145-151
pubmed: 18304834
Am J Respir Cell Mol Biol. 2002 Feb;26(2):224-30
pubmed: 11804874
Tissue Eng Part C Methods. 2015 Nov 19;22(2):132-141
pubmed: 26443415
Materials (Basel). 2018 Oct 11;11(10):
pubmed: 30314394
Eur Cell Mater. 2016 May 24;31:312-22
pubmed: 27215739
Nat Rev Rheumatol. 2018 Oct;14(10):592-602
pubmed: 30190520
J Funct Biomater. 2019 Apr 25;10(2):
pubmed: 31027151
Mater Sci Eng C Mater Biol Appl. 2020 Aug;113:110983
pubmed: 32487397
J Biomed Mater Res A. 2008 Mar 1;84(3):682-90
pubmed: 17635019
Trends Biochem Sci. 2019 Jul;44(7):616-628
pubmed: 30799235
Tissue Eng Part A. 2015 Jan;21(1-2):115-23
pubmed: 24980654
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26660-26671
pubmed: 33046631
Integr Biol (Camb). 2013 Jul 24;5(7):920-31
pubmed: 23752904
Tissue Eng Part B Rev. 2008 Jun;14(2):179-86
pubmed: 18544015
PLoS One. 2013 Sep 18;8(9):e75227
pubmed: 24058665
Biomed Pharmacother. 1990;44(9):467-74
pubmed: 2127902
Bone. 2017 May;98:38-46
pubmed: 28286238
Cell Tissue Res. 2017 Aug;369(2):273-286
pubmed: 28361303
Biomaterials. 2014 Dec;35(37):9853-9867
pubmed: 25201737
J Tissue Eng Regen Med. 2018 Jul;12(7):1728-1741
pubmed: 29766675